Next Article in Journal
An Enhanced Self-Care Protocol for People Affected by Moderate to Severe Lymphedema
Previous Article in Journal
Large Field Alpha Irradiation Setup for Radiobiological Experiments
Protocol

Quantifying Fluorescently Labeled Ceramide Levels in Human Sarcoma Cell Lines in Response to a Sphingomyelin Synthase Inhibitor

Department of Biomedical and Pharmaceutical Sciences, Idaho State University, Pocatello, ID 83209, USA
*
Author to whom correspondence should be addressed.
Methods Protoc. 2019, 2(3), 76; https://doi.org/10.3390/mps2030076
Received: 31 May 2019 / Revised: 12 August 2019 / Accepted: 29 August 2019 / Published: 31 August 2019
Sphingolipid metabolism is an important process in sustaining the growth needs of rapidly dividing cancer cells. Enzymes that synthesize sphingolipids have become attractive targets in cancer pharmacology. Ceramide is a precursor for synthesizing sphingolipids such as sphingomyelin, sphingosine-1-phosphate, and glucosylceramide. Sphingomyelin synthase (SMS) is the enzyme that transfers a phosphatidylcholine to ceramide to generate sphingomyelin. To test the inhibition of SMS, scientists assess the buildup of ceramide in the cell, which is cytotoxic. Because ceramide is a small lipid molecule, there are limited tools like antibodies to detect its presence. Alternatively, designated machines for small-molecule separation coupled with mass spectrometry detection can be used; however, these can be cost-prohibitive. We used a commercially available NBD-ceramide to apply to human cancer cell lines in the presence or absence of a known SMS inhibitor, jaspine B. After short incubation times, we were able to collect cell lysates and using solvent extraction methods, run the cellular material on a thin-layer chromatography plate to determine the levels of intact fluorescently labeled ceramide. Brighter fluorescence on the TLC plate correlated to greater SMS inhibition. Small molecules can then be screened quantifiably to determine the biological impact of inhibiting the sphingolipid metabolism pathways involving ceramide. View Full-Text
Keywords: ceramide; synovial sarcoma; osteosarcoma; sphingomyelin synthase inhibitor; jaspine B; cellular assay ceramide; synovial sarcoma; osteosarcoma; sphingomyelin synthase inhibitor; jaspine B; cellular assay
Show Figures

Figure 1

MDPI and ACS Style

Pashikanti, S.; Afrin, F.; Meldrum, T.C.; Stegelmeier, J.L.; Pavek, A.; Habashi, Y.A.; Fatema, K.; Barrott, J.J. Quantifying Fluorescently Labeled Ceramide Levels in Human Sarcoma Cell Lines in Response to a Sphingomyelin Synthase Inhibitor. Methods Protoc. 2019, 2, 76. https://doi.org/10.3390/mps2030076

AMA Style

Pashikanti S, Afrin F, Meldrum TC, Stegelmeier JL, Pavek A, Habashi YA, Fatema K, Barrott JJ. Quantifying Fluorescently Labeled Ceramide Levels in Human Sarcoma Cell Lines in Response to a Sphingomyelin Synthase Inhibitor. Methods and Protocols. 2019; 2(3):76. https://doi.org/10.3390/mps2030076

Chicago/Turabian Style

Pashikanti, Srinath, Farjana Afrin, Trevor C. Meldrum, John L. Stegelmeier, Adriene Pavek, Yashar A. Habashi, Kaniz Fatema, and Jared J. Barrott 2019. "Quantifying Fluorescently Labeled Ceramide Levels in Human Sarcoma Cell Lines in Response to a Sphingomyelin Synthase Inhibitor" Methods and Protocols 2, no. 3: 76. https://doi.org/10.3390/mps2030076

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop